Search results
Career. Löwenberg is a professor of hematology at Erasmus University Rotterdam, the Netherlands, since 1990, and was department chair of hematology during 1990–2011. [1] Between 1980 and 1990 he had been the scientific director of the Rotterdam Daniel den Hoed Cancer Center, now known as the Erasmus MC. From 2013 to 2020 he served as the ...
Education and career. 1990 - : Professor of Hematology, Department of Hematology, Erasmus University Medical Center, Rotterdam. 1983 - 1986 : Visiting Professor, Free University Brussel. 1982 - 1990 : Director of Research, Daniel den Hoed Cancer Center, Rotterdam. 2000 - 2011 : Chair Cluster Hematology-Oncology, Erasmus University Medical ...
Bob Löwenberg’s research is concerned with developmental diagnostics and therapeutics, in particular in acute myeloid leukemia (AML) in the context of single center and multicenter prospective clinical trials. These trials evaluate novel agents and novel therapeutic approaches with account of the molecular heterogeneity of the disease.
Inspire2Live has known Professor Löwenberg, or ‘Bob’ as he is known to us, for a long time. His passion for patients is enormous. His drive to improve the patient treatment outcome is one of the reasons he works so closely with our organisation and our patient advocates because he really knows what patients need.
Feb 24, 2019 · Bob Löwenberg, MD, PhD, is a Principal Investigator & Professor of Hematology in the Department of Hematology at the Erasmus University Medical Center, Erasmus University, Rotterdam, Netherlands, where he has worked since 1990. Prof. Löwenberg was Chair Cluster of Hematology-Oncology at Erasmus University Medical Center from 2000-2011. From ...
Dive into the research topics where Bob Löwenberg is active. These topic labels come from the works of this person. Together they form a unique fingerprint. 1 Similar Profiles. Acute Myeloid Leukemia Medicine and Dentistry 100%. Myeloid Biochemistry, Genetics and Molecular Biology 83%. Minimal Residual Disease Medicine and Dentistry 30%.
Bob Löwenberg. The affordability of newly approved anticancer agents is a challenge to many national health services and reimbursement systems. Therefore, we have developed an approach based upon ...
